Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. [electronic resource]
Producer: 20201030Description: 379-385 p. digitalISSN:- 1095-6859
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bevacizumab -- administration & dosage
- Carcinoma, Ovarian Epithelial -- drug therapy
- Drug Resistance, Neoplasm
- Female
- Folate Receptor 1 -- immunology
- Humans
- Immunoconjugates -- administration & dosage
- Maytansine -- administration & dosage
- Middle Aged
- Organoplatinum Compounds -- pharmacology
- Ovarian Neoplasms -- drug therapy
- Progression-Free Survival
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.